Table 4.
Mean percent change from baseline CYP1A2 activity in smokers, switchers to THS, and abstainers in PMI’s clinical studies (per protocol populations).
| Study | Day 5 |
Day 90 |
||||
|---|---|---|---|---|---|---|
| THS | CC | SA | THS | CC | SA | |
| % change (95 % CI) | % change (95 % CI) | % change (95 % CI) | % change (95 % CI) | % change (95 % CI) | % change (95 % CI) | |
| 5-day Poland (30) | −16.51 (-20.536, -12.481) | 12.71 (7.705, 17.724) | −14.86 (-20.053, -9.667) | NA | NA | NA |
| 5-day Japan (29) | −27.36 (-30.507, -24.216) | −0.99 (-5.964, 3.985) | −30.46 (-35.314, -25.609) | NA | NA | NA |
| 90-day Japan (31) | −21.75 (-25.24, -18.26) | 9.65 (2.43, 16.86) | −23.81 (-29.21, -18.41) | −20.22 (-26.66, -13.78) | 15.77 (3.24, -28.30) | −15.82 (-23.19, -8.46) |
| 90-day U.S. (32) | −32.81 (-36.702, -28.923) | 3.56 (-1.121, 8.233) | −34.53 (-39.631, -29.433) | −31.96 (-40.407, -23.503) | −16.71 (-23.868, -9.545) | −35.36 (-53.476, -17.243) |